Evidence map›Paper›PMID 33442358›Full record

ArticleCase reports in oncology

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor.

Simon Häfliger, Ann-Katrin Seidel, Eric Schoch, Jan Reichmann, Damian Wild, Stephanie Steinmann-Schwager, Miklos Pless

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Treatment Advances in Tumor-Induced Osteomalacia.Calcified tissue international · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Simon HäfligerDepartment of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Ann-Katrin SeidelDepartment of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Eric SchochDepartment of Radiology, Kantonsspital Winterthur, Winterthur, Switzerland.
Jan ReichmannDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Damian WildDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Stephanie Steinmann-SchwagerHausärzte am Bahnhofplatz, General Medicine Office, Winterthur, Switzerland.
Miklos PlessDepartment of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting syndrome. Upon complete surgical removal of the tumor, FGF-23 normalizes and the osteomalacia is cured. In cases in which surgery is not feasible, radiofrequency ablation (RFA) is the treatment of choice. We describe a case with a PMT situated in the sacrum, in close proximity to the sacral plexus. Both surgery and RFA were considered potentially nerve damaging. Since the tumor showed expression of somatostatin receptors, we opted for a peptide receptor radionuclide therapy (PRRT) with

Indexed as

DOTATOCPeptide receptor radionuclide therapyPhosphaturic mesenchymal tumorRadiofrequency ablationTumor-induced osteomalacia

Identifiers

PMID33442358
PMCPMC7772845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.